key: cord-0851053-oamrgm5p
authors: Laure, Gallay; Viet-Thi, Tran; Elodie, Perrodeau; Nicolas, Vignier; Matthieu, Mahevas; Francesca, Bisio; Emmanuel, Forestier; Francois-Xavier, Lescure
title: 14-Day survival among older adults with severe SARS-Cov2 infection treated with corticosteroid: a cohort study
date: 2021-04-02
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.03.021
sha: 82d645477a9ef1e8bd9d953565720d0d0da5fad1
doc_id: 851053
cord_uid: oamrgm5p

OBJECTIVE: To assess the effectiveness of corticosteroids among older adults with COVID-19 pneumonia requiring oxygen. METHODS: We used routine care data from 36 hospitals in France and Luxembourg to assess the effectiveness of corticosteroids at 0.4 mg/kg/day eq. prednisone (treatment group) versus standard of care (control group) among adults [Formula: see text] 80 years old with PCR-confirmed SARS-CoV-2 infection or CT-scan images typical of COVID-19 pneumonia, requiring oxygen ≥ 3 L/min, and with an inflammatory syndrome (C-reactive protein ≥ 40 mg/L). The primary outcome was overall survival at day 14. In our main analysis, characteristics of patients at baseline (i.e., time when patients met all inclusion criteria) were balanced by using propensity-score inverse probability of treatment weighting. RESULTS: Among the 267 patients included in the analysis, 98 were assigned to the treatment group. Their median age was 86 years (interquartile range 83 to 90), and 95% had a SARS-CoV-2 PCR-confirmed diagnosis. In total, 43/98 (43.9%) patients in the treatment group and 84/166 (50.6%) in the control group died before day 14 (weighted hazard ratio [wHR] 0.67, 95% CI 0.46 to 0.99). The treatment and control groups did not differ significantly for the proportion of patients discharged to home/rehabilitation at day 14 (wRR 1.12, 95% CI 0.68 to 1.82). Twenty-two (16.7%) patients receiving corticosteroids developed adverse events, but only 11 (6.4%) from the control group. CONCLUSIONS: Corticosteroids were associated with a significant increase in the overall survival at day 14 of patients aged 80 years and older hospitalised for severe COVID-19.

The RECOVERY trial showed that dexamethasone reduced mortality for patients with coronavirus disease 2019 (COVID-19) receiving oxygen with and without invasive mechanical ventilation [1] . The efficacy of corticosteroids in critically ill patients was confirmed in subsequent studies [2] [3] [4] . However, for patients with less severe disease, studies have showed variable effectiveness, associated with the severity of the disease: the more severely ill the patients, the more effective the treatment [1, 5, 6] .

In older adults, who are at the greatest risk of severe disease and death from COVID-19, the RECOVERY trial is the only study reporting results for patients outside critical care, and it found no difference in the survival of patients according to their treatment by dexamethasone [1, 7] . Nonetheless, the heterogeneity in the severity of infection within this specific subgroup does not justify strong conclusions. The unclear benefit-risk balance of corticosteroids for older patients has raised concerns (e.g., because these drugs increase the risk of confusion, hyperglycaemia, falls, drug-drug interactions, etc.) and some countries, including France, do not support the systematic use of corticosteroids for patients aged ≥ 70 years despite recommendations from the WHO to treat all adult patients with severe and critical with systemic corticosteroids [8] .

In this study, we used routine care data collected during the first acute phase of the pandemic to retrospectively emulate a target trial aimed at assessing the effectiveness of corticosteroids for severe SARS-CoV-2 infection in older adults.

Physicians screened one by one all patients hospitalised between 14 March and 30 April, 2020. First, they identified all consecutive patients aged 80 years or older, with a SARS-CoV-2 infection confirmed by PCR or by typical clinical and CT-scan findings. Second, they assessed whether these patients had a severe COVID-19 infection, defined by both an oxygen requirement ≥3 L/min (regardless of its duration) and C-reactive protein ≥40 mg/L [9] . Third, they excluded patients with organ failure at baseline including those who required immediate admission to the ICU and those requiring non-invasive ventilation. Physicians and research assistants then used patients' electronic health records to abstract their data.

The Institutional Review Board of Henri-Mondor Hospital (AP-HP), France, approved this study (number: 00011558). As it was based on data from routine care already collected at the J o u r n a l P r e -p r o o f time of the study, patients' informed consent was not required. All patients or family members were informed that their hospital data would be used for research purposes and were offered the opportunity to object to the use of their data.

We compared two treatment strategies: receiving at least one dose of corticosteroids ≥0.4 mg/kg/day eq. prednisone (treatment group), or receiving the standard of care (control group).

The cut-off value of 0.4 mg/kg/day was chosen to take dose rounding by physicians into account. To emulate a pragmatic trial, patients in the treatment group could start corticosteroids within a "grace period" of 72 hours from baseline.

Our causal contrast of interest was the per-protocol effect, and we compared participants who received corticosteroids in the 72 hours after baseline with hose who did not receive this drug. A specific sensitivity analysis mimicking an intention-to-treat analysis was performed, analysing all patients eligible for the study; those whose data did not meet the criteria for treatment were analysed in the control group. For safety outcomes, all patients who received corticosteroids before Day 14, regardless of its dose or timing, were included in the treatment group. The definition of group assignment based on patients' observational data is reported in Table S1 .

The start of follow-up (baseline or time zero) for each individual was the time when all eligibility criteria (oxygen therapy ≥ 3 L/min and inflammatory syndrome with a CRP level ≥ 40 mg/L) were met. A l patients were followed up from baseline until the occurrence of one of the following events, whichever came first: (1) death, (2) loss to follow-up, or (3) end of follow-up, which occurred at least 14 days after baseline.

The primary outcome was overall survival by day 14. The secondary outcome was the proportion of patients discharged from hospital to home/rehabilitation on day 14. The time frame of 14 days was chosen because at the time of the study and in the frail population of patients ≥ 80 years old, most deaths occurred before day 14 [10] . All adverse events were abstracted from electronic health records in free text and independently recoded by one physician (VTT).

Propensity-score methods were used to account for differences between the two groups at baseline. The propensity score represents the probability that patients would receive corticosteroids, given their baseline demographic and clinical covariates (Supplementary Text S2). Estimates of the average treatment effect were calculated by inverse probability of treatment weighting (IPTW), with Cox proportional hazards models calculating hazard ratios (wHR) and IPTW estimates of the relative risk (wRR) for binary outcomes.

To account for immortal time bias, all patients in the control group who died during the grace period were randomly assigned to one of the two groups, given that their observational data were compatible with both groups at the time of the event (Supplementary Text S3) [11, 12] .

Missing baseline variables were handled by using multiple imputation with chained equations.

The Institutional Review Board of Henri Mondor Hospital approved the study (N 00011558).

This study included 267 patients. Their median age was 86 years (interquartile range [IQR], 83 to 90), 49.8% were men, 95% had a SARS-CoV-2 PCR-confirmed diagnosis, and 98 were assigned to the treatment group (Supplementary Figure S4, Supplementary materials S5) .

Comorbidities and clinical severity at baseline were similar between the two groups.

However, corticosteroids were prescribed less often to patients with low autonomy at baseline, measured with the Groupe Iso Ressource (GIR) score; 14.3% of patients in the treatment group and 20.9% in the control group had a GIR score of 1 or 2, which indicates low autonomy.

The median time from symptom onset to baseline was 7 days (IQR, 4 to 10). Among the 98 patients assigned to the treatment group, 51 (53.7%) received methylprednisolone, 22 (23.2%) prednisone, 15 (15.8%) dexamethasone, 4 (4.2%) prednisolone, and 3 (3.2%) hydrocortisone.

The median duration of corticosteroid treatment was 5 days (IQR 3-11) and the median dose of corticosteroids 1.1 mg/kg/day eq. prednisone (IQR 0.9-1.6), that is, 0.2 mg/kg of dexamethasone per day ( Table 1) .

Vital status was missing at day 14 for three of the 267 patients included in the main analysis (who had, however, been discharged in good health status before this date). During follow-up, 7 patients were transferred to ICU, 1 was intubated and 127 died before day 14.

In total, 43/98 (43.9%) patients in the treatment group and 84/166 (50.6%) in the control group died before day 14 (HR 0.81, 95% CI 0.56 to 1.16). After balancing the baseline covariates by IPTW, survival was significantly higher for patients from the treatment group compared with the control group: wHR 0.67, 0.46 to 0.99 (Figure) . There was no significant difference between the treatment and control groups for the proportion of patients discharged to home/rehabilitation at day 14 (wRR 1.12, 95% CI 0.68 to 1.82) 

In this emulated trial, corticosteroids significantly improved the 14-day survival of patients aged 80 years or older and hospitalised in a non-ICU department for severe COVID-19. It is worth noting that our findings emphasise an important survival benefit together with reassuring data regarding harms. Indeed, despite patients treated with corticosteroids experienced more adverse events than those treated with the standard of care, those effects remained rare and there was no major cardio-or neurotoxicity. Our study did not show a reduction in hospitalisation length, but the end point at day 14 might have been too early to identify this. Such an effect would be important in reducing the geriatric complications of longer hospitalisations such as functional decline, decreased nutrition, and cognitive impairment [13] .

Recommendations to treat older patients with corticosteroids have been based on results from studies performed in ICU [2] and on results from the RECOVERY trial, which showed an overall effect of dexamethasone, but a non-significant difference in the population of patients aged 80 years or more. The discrepancy with our findings may be explained by two points: 1) our study population was more homogenous and more severely ill than that studied in the J o u r n a l P r e -p r o o f RECOVERY trial (35% of the patients older than 80 years in the RECOVERY trial were not under oxygen at randomisation); and 2) both the RECOVERY trial and the COCORICO study have shown that the more severely ill the patients are, the more effective corticosteroids [1, 5] .

Our study has from several limitations. Despite the use of robust methods to draw causal inferences, the study remains observational and potential unmeasured confounders may bias the results [14] . Moreover, the corticosteroid prescriptions were heterogeneous in terms of drugs, time of start, dose, and duration. Third, we could not account for the duration of corticosteroid prescriptions. For example, we may have observed only 3 days of corticosteroid treatment for a given patient because an event occurred on the fourth day. Fourth, our study population might not be representative of the population of older adults hospitalised during the first wave in France because it was recruited in centres involved in a network coordinated by REACTing (INSERM), which involved mainly non-geriatric wards. Fifth, our study was limited to the number of eligible patients available at the time of analysis. In particular, we found discrepant results between the main analysis and the sensitivity analyses. This may suggest that survivor bias is not completely accounted for in the main analysis or that our study lacked power. Finally, the follow up was limited to 14 days. Nonetheless, evidence shows that at the time of the study most deaths occurred before this cut-off point [10] .

In all, our findings support the use of corticosteroids for patients aged 80 years or older with severe COVID-19. However, further research is needed to determine the right timing and dose of the treatment as wel as the right indication, especially to clarify the benefit-risk balance. In particular, it would be interesting to assess whether its use in nursing homes could reduce the transfer of older adults with severe disease to the hospital. Strengthening the therapeutic arsenal for the care of older adults is critical as these patients are the most vulnerable to COVID-19 and may not fully benefit from vaccination because of the immune-senescence associated with advanced age [15] .

Concept and design: Lescure FX, Gallay L, Tran VT. Acquisition, analysis, or interpretation of data: All authors from the COCO_OLD Study Group. Drafting of the manuscript: Tran VT, Lescure FX, Forestier E, Gallay L, Bisio F, Vignier N., Mahevas M. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Tran VT, Perrodeau E.

Administrative, technical, or material support: Lescure FX, Gallay L, Tran VT, Forestier E. Supervision: Lescure FX. Dr Tran and Ms. Perrodeau had full access to all the data of the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

No external funding was received for this study.

Dr. GALLAY has nothing to disclose. Dr. TRAN is a minority shareholder from SKEZI, this activity is outside the submitted work. Ms. PERRODEAU has nothing to disclose. Dr.

VIGNIER has nothing to disclose. Dr MAHEVAS received research funds from GSK, outside the submitted work; personal fees for lectures from LFB and Amgen, outside of the submitted word. Dr. BISIO has nothing to disclose. Dr. FORESTIER has nothing to disclose. Dr LESCURE received personal fees for lectures from Gilead Sciences, bioMerieux and MSD, outside of the submitted work. Abbreviations: IQR, interquartile range; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers. Results are presented as % (count) unless stated otherwise. *This corresponds to 95 patients receiving corticosteroids with at least 0.4 mg/kg in the 72 h after baseline + 1 patient from the control group randomly assigned to the treatment group to account for immortal time bias (see the detailed methods in Supplementary materials). ** 77 patients did not have a CT scan at admission. 

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

Effect of Dexamethasone on Days Alive

Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data

Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicenter study

COVID-19 and Older Adults: What We Know

Utilisation de la dexaméthasone et d autres corticoïdes dans le Covid-19

Longitudinal changes of inflammatory parameters and their co relation with disease severity and outcomes in patients with COVID-19 from Wuhan

Estimating the burden of SARS-CoV-2 in France

Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses

An observational cohort study of hydroxychloroquine and azithromycin for COVID-19: (Can't Get No) Satisfaction

A new paradigm for clinical investigation of infectious syndromes in older adults: assessment of functional status as a risk factor and outcome measure

The C-Word: Scientific Euphemisms Do Not Improve Causal Inference From Observational Data

The Exclusion of Older Persons From Vaccine and Treatment Trials for Coronavirus Disease 2019-Missing the Target

Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology